Navigation Links
Thoratec Announces $30 Million Accelerated Share Repurchase
Date:8/6/2014

te at http://www.thoratec.com.

Thoratec, the Thoratec logo, and HeartMate II are registered trademarks of Thoratec Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC, and PediVAS is a registered trademark of Thoratec Switzerland GmbH.

The preceding paragraphs contain forward-looking statements within the meaning of Sections 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements can be identified by the words, "believes," "views," "expects," "plans," "projects," "should," "hopes," "could," "will," "may," "estimates," "potential," and other similar words. Actual results, events or performance could differ materially from these forward-looking statements based on a variety of factors, many of which are beyond Thoratec's control. Therefore, readers are cautioned not to put undue reliance on these statements. Investors are cautioned that all such statements involve risks and uncertainties, including risks related to regulatory approvals, the development of new products, including development and clinical trial timing, the growth of existing markets for our products, customer and physician acceptance of Thoratec products, the effects of FDA or foreign regulatory authority requirements, our ability to address quality issues adequately and on a timely basis without a resulting recall of products or interruption of manufacturing or shipment of products, the effects of healthcare reimbursement and coverage policies, and the effects of competition. Forward-looking statements contained in this press release should be considered in light these factors and those factors discussed from time to time in Thoratec's public reports filed with the Securities and Exchange Commission, such as those discussed under the heading, "Risk Factors," in Thoratec's most recent annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and
'/>"/>

SOURCE Thoratec Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Thoratec Reports First Quarter 2012 Results
3. Thoratec Schedules Second Quarter Conference Call, Webcast
4. Thoratec Reports Second Quarter Results
5. Thoratec Announces Presentations At Upcoming Investor Conferences
6. Thoratec Reports Third Quarter Results
7. Thoratec Presentation At Credit Suisse 2012 Healthcare Conference To Be Webcast
8. Thoratec Presentation At Piper Jaffray 24th Annual Healthcare Conference To Be Webcast
9. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
10. Thoratec Schedules Fourth Quarter Conference Call, Webcast
11. Thoratec Presentation at Leerink Swann Global Healthcare Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... ... September 01, 2015 , ... As ... Cross and Blue Shield of Minnesota (Blue Cross) has announced Doctor On Demand ... in San Francisco, Doctor On Demand provides immediate access to Board Certified physicians ...
(Date:9/1/2015)... Houston, TX (PRWEB) , ... September 01, 2015 ... ... announce that it is now offering the MonaLisa Touch® , an innovative ... , The MonaLisa Touch® is a new hormone-free treatment for atrophic vaginitis, a ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, ... of pet vital signs and activity, today announced its integration with leading veterinary ... popular and widely-adopted veterinary hospital Practice Management Software packages in the US. Practice ...
(Date:9/1/2015)... ... ... Royal River Natural Foods, a locally-owned independent natural health store in Freeport, ... and found that, among those who had a stroke, people who used multivitamins survived ... the September 2015 issue of “Natural Insights for Well Being,” which Royal River Natural ...
(Date:9/1/2015)... ... 01, 2015 , ... Two of Washington D.C.’s most respected chefs are using ... , Recently named “the next big thing” in the culinary world by Elle ... whole story behind food and reclaiming culinary traditions on the brink of extinction. According ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 2Health News:Blue Cross and Blue Shield of Minnesota names Doctor On Demand as preferred telehealth destination 3Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 2Health News:Houston's Plaza OB/GYN Now Offering the MonaLisa Touch® 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 2Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 3Health News:Chefs Amy Riolo and Luigi Diotaiuti Embark on Culinary Diplomatic Quest to Build Bridges through Global Cuisine 4
... , , NAPLES, ... of dementia among the elderly and is projected to increase in ... an urgent need for treatments that will prevent or reverse the ... synthetic drugs is expensive and complex, many researchers are focusing on ...
... N.J., Sept. 3 CANTEL MEDICAL CORP. (NYSE: ... CEO, will be presenting at the CL King 7th Annual Best ... on Thursday, September 17, 2009 at the Omni Berkshire Place Hotel ... following the presentation. In addition, Mr. Krakauer and Seth R. Segel, ...
... PTSD, experts say , THURSDAY, Sept. 3 (HealthDay News) -- ... racing dangerously down the freeway at 85 miles an hour ... She immediately slowed down. , The wet nose belonged to ... levels were rising, a dangerous state given that Pacanowski has ...
... , FRANKLIN, Mass., Sept. 3 ... ECTE), a diabetes management company developing the ... continuous glucose monitoring (tCGM) system and the Prelude(TM) SkinPrep ... that Patrick T. Mooney, M.D., Chairman and Chief Executive ...
... CARY, N.C., Sept. 3 Cornerstone Therapeutics Inc. ... on acquiring, developing and commercializing significant products primarily for the ... Chief Executive Officer, will be presenting a corporate overview at ... Mr. Collard will first present at the Thomas Weisel Partners ...
... , EMERYVILLE, Calif., Sept. 3 Bionovo, Inc. (Nasdaq: ... the phase 2 clinical trial of their lead drug candidate for postmenopausal ... for Gynecology (EGS) in Rome, Italy. , , ... safety and efficacy of two doses of Menerba versus placebo. The trial ...
Cached Medicine News:Health News:HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid-Beta Accumulation, a Hallmark of Alzheimer's Disease 2Health News:HerbalScience Research Demonstrates that Optimized Turmeric Extract Inhibits Amyloid-Beta Accumulation, a Hallmark of Alzheimer's Disease 3Health News:Service Dogs Help Traumatized Veterans Heal 2Health News:Service Dogs Help Traumatized Veterans Heal 3Health News:Echo Therapeutics to Present at Rodman & Renshaw 2009 Annual Global Investment Conference 2Health News:Cornerstone Therapeutics to Present at Two Upcoming Investor Conferences 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 2Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 3Health News:Bionovo to Present Positive Results from Phase 2 Trial of Menerba for Vasomotor Symptoms to the International Community 4
... The SeedVac™ is a vacuum driven device designed to ... tube tip. Seeds are drawn into the clear tube ... the hand piece to create the vacuum. The prescribed ... the clear tube tip before being placed into the ...
MT-BT-5001-25 prostate seeding needle (set of 25 unloaded needles).,MT-BT-5001-P prostate seeding needle, pre-plugged and pre-sterilized, unloaded or for use with MEDTECs ASAP™ pre-load seeding...
... a myoma was performed with a cutting ... vaporization of myomas with the VaporTrode Vaporization ... tissue chips that obscure visibility. No tissue ... This unique design provides areas of high ...
... The 19 Fr. OES 4000 Nephroscope, with ... quality with outstanding durability. The lumbotome, for ... the telescopic bougies, allow safer access. The ... comprehensive range of grasping forceps and lithotripsy ...
Medicine Products: